Onconetix Shifts Focus to Prostate Cancer Diagnostic, Dumps BPH Drug

TL;DR

**ONCO is ditching its BPH drug to go all-in on a prostate cancer diagnostic, a high-risk pivot that could make or break the company.**

AI Summary

Onconetix, Inc. (ONCO) filed an S-1/A on December 22, 2025, registering 29,778,195 shares of common stock for resale by Selling Stockholders. This includes up to 20,039,930 shares from Series D preferred stock and warrants issued in a September 22, 2025 private placement, and up to 9,496,751 shares from Series E preferred stock and warrants issued in an October 1, 2025 private placement. Additionally, 241,514 shares were issued to Altos Venture AG in connection with a December 15, 2023 Share Exchange Agreement. The company will not receive proceeds from the resale of these shares, only from the cash exercise of PIPE Warrants. Onconetix has abandoned commercialization of its FDA-approved BPH treatment, ENTADFI, due to time, resource, and cash runway constraints, fully impairing ENTADFI assets by June 30, 2024, and terminating three related employees. The company is now focusing solely on commercializing Proclarix, an in vitro diagnostic test for prostate cancer acquired through Proteomedix, which is approved in the EU and anticipated for U.S. marketing via LabCorp. Onconetix reported a net loss of $(9,716) for the three months ended March 31, 2025, compared to $(11,119) for the same period in 2024, and a net loss of $(58,897) for the year ended December 31, 2024. The company underwent a 1-for-85 reverse stock split on June 13, 2025.

Why It Matters

This S-1/A signals a critical strategic pivot for Onconetix, abandoning its FDA-approved ENTADFI product to focus entirely on Proclarix, a prostate cancer diagnostic. For investors, this means a complete re-evaluation of ONCO's market potential, shifting from a pharmaceutical play to a diagnostics company. Employees involved with ENTADFI have been terminated, impacting morale and expertise. Customers who might have benefited from ENTADFI will see it disappear, while new patients could gain access to Proclarix, potentially reducing unnecessary prostate biopsies. In the competitive diagnostics market, Onconetix's success hinges on Proclarix's adoption against established and emerging diagnostic tools.

Risk Assessment

Risk Level: high — The company explicitly states its 'need to raise substantial additional capital to fund our operations' and its 'ability to continue as a going concern' are significant risks. The abandonment of ENTADFI, leading to full impairment of assets by June 30, 2024, and employee terminations, highlights severe financial distress and a high-risk, single-product strategy with Proclarix. The last reported sale price of ONCO common stock was $1.84 per share on December 18, 2025, indicating significant market skepticism.

Analyst Insight

Investors should approach ONCO with extreme caution, recognizing the high-risk nature of its strategic pivot and financial instability. Monitor the commercialization progress of Proclarix closely, specifically its uptake through LabCorp, and any future capital raises. This is a speculative play, suitable only for investors with a high-risk tolerance.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$(9,716)

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 29,778,195 — Shares of Common Stock (Registered for resale by Selling Stockholders)
• 20,039,930 — Shares of Common Stock (Issuable from Series D preferred stock and warrants)
• 9,496,751 — Shares of Common Stock (Issuable from Series E preferred stock and warrants)
• 241,514 — Shares of Common Stock (Issued to Altos Venture AG)
• $3.6896 — Initial exercise price (Series D Warrant and conversion price of Series D Preferred Stock)
• $3.8576 — Initial exercise price (Series E Warrant and conversion price of Series E Preferred Stock)
• $1.84 — Last reported sale price (ONCO Common Stock on December 18, 2025)
• $(9,716) — Net loss (For the three months ended March 31, 2025)
• $(58,897) — Net loss (For the year ended December 31, 2024)
• 1-for-85 — Reverse Stock Split (Effected on June 13, 2025)

Key Players & Entities

• Onconetix, Inc. (company) — Registrant and issuer of common stock
• Karina M. Fedasz (person) — Interim Chief Executive Officer and Interim Chief Financial Officer
• Proteomedix AG (company) — Acquired company, developer of Proclarix
• Altos Venture AG (company) — Recipient of 241,514 shares of Common Stock in a Share Exchange Agreement
• Laboratory Corporation of America (company) — Third-party licensee for U.S. marketing of Proclarix
• The Nasdaq Capital Market (regulator) — Listing exchange for ONCO common stock
• Ellenoff Grossman & Schole LLP (company) — Legal counsel for Onconetix, Inc.
• Barry I. Grossman, Esq. (person) — Legal counsel for Onconetix, Inc.
• Jessica Yuan, Esq. (person) — Legal counsel for Onconetix, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company has a history of net losses and has abandoned a key commercialization effort (ENTADFI). This indicates a significant need for ongoing capital to fund operations and the development of Proclarix. Failure to secure additional financing could jeopardize the company's ability to continue as a going concern.
• Commercialization Strategy Shift [high — operational]: Onconetix has pivoted from its FDA-approved BPH treatment, ENTADFI, to focus solely on Proclarix. This shift, driven by resource and cash runway constraints, introduces execution risk in commercializing a new diagnostic test. The success of Proclarix is now critical to the company's future.
• Regulatory Approval and Market Access for Proclarix [medium — regulatory]: While Proclarix is approved in the EU, U.S. marketing is anticipated via LabCorp. The company faces regulatory hurdles and market access challenges in the U.S. for Proclarix, which could impact its revenue generation potential.
• Dilution from Share Resales [medium — financial]: The S-1/A registers nearly 30 million shares for resale by existing stockholders. This large volume of shares, if sold, could exert downward pressure on the stock price and dilute existing shareholders' ownership percentage.
• Key Personnel and Asset Impairment [medium — operational]: The company fully impaired ENTADFI assets and terminated three related employees. This indicates significant restructuring and potential loss of institutional knowledge, which could impact operational efficiency and future strategic decisions.

Industry Context

Onconetix operates in the highly competitive healthcare sector, specifically focusing on diagnostics and previously on therapeutics. The diagnostic market, particularly for cancer detection like prostate cancer, is driven by technological innovation, clinical utility, and reimbursement policies. The shift from a therapeutic focus (ENTADFI) to a diagnostic focus (Proclarix) reflects a strategic pivot common in biotech/medtech companies facing resource constraints, aiming for a potentially faster path to market and revenue generation.

Regulatory Implications

The company's reliance on regulatory approvals (EU for Proclarix, anticipated U.S. via LabCorp) and the abandonment of an FDA-approved product highlight significant regulatory risks. Future commercial success hinges on navigating U.S. regulatory pathways for diagnostics and maintaining compliance with evolving healthcare regulations.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2023-12-15: Share Exchange Agreement with Altos Venture AG — Resulted in the issuance of 241,514 shares, impacting the company's capital structure.
• 2024-06-30: Full impairment of ENTADFI assets — Signaled the abandonment of a key commercialization strategy due to resource and cash constraints.
• 2025-03-31: Three months ended net loss reported — Indicates ongoing operational losses, with a net loss of $(9,716) for the period.
• 2025-06-13: 1-for-85 reverse stock split — Aimed at increasing the per-share price of common stock, often a precursor to or consequence of financial distress or listing requirements.
• 2025-09-22: Series D private placement — Issued preferred stock and warrants, registering up to 20,039,930 shares for resale.
• 2025-10-01: Series E private placement — Issued preferred stock and warrants, registering up to 9,496,751 shares for resale.
• 2025-12-22: S-1/A filing — Registered nearly 30 million shares for resale by Selling Stockholders, indicating potential liquidity events for early investors and significant dilution for public shareholders.

Glossary

S-1/A

An amended registration statement filed with the SEC, typically used when a company is going public or registering securities for resale. (This filing details the securities being registered for resale and provides updated financial and business information.)

Selling Stockholders

Existing shareholders who are offering their shares for sale to the public, as opposed to the company selling new shares. (The company will not receive proceeds from these sales; the focus is on the resale of shares from private placements and other issuances.)

Series D/E Preferred Stock

Classes of preferred stock issued in private placements, often with specific rights and conversion features into common stock. (These issuances are a primary source of the shares being registered for resale, along with associated warrants.)

PIPE Warrants

Warrants issued in a Private Investment in Public Equity (PIPE) transaction, giving the holder the right to purchase common stock at a specified price. (The company may receive proceeds from the cash exercise of these warrants, representing a potential, albeit limited, source of capital.)

Reverse Stock Split

A corporate action where a company reduces the number of outstanding shares by consolidating them, increasing the per-share price. (Onconetix executed a 1-for-85 reverse split, significantly altering its share structure and potentially impacting investor perception.)

BPH

Benign Prostatic Hyperplasia, a common non-cancerous enlargement of the prostate gland in men. (ENTADFI, a treatment for BPH, was a key product that Onconetix has abandoned commercialization of.)

In Vitro Diagnostic Test

A medical device used to perform tests on samples such as blood or tissue taken from the human body to help diagnose diseases or conditions. (Proclarix, Onconetix's current focus, is an in vitro diagnostic test for prostate cancer.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (The company's financial situation and abandonment of a product raise questions about its ability to continue as a going concern without further financing.)

Year-Over-Year Comparison

This S-1/A filing represents a significant strategic shift compared to previous disclosures. The company has abandoned its BPH treatment, ENTADFI, leading to full asset impairment and workforce reduction. The focus has entirely shifted to the commercialization of Proclarix, an in vitro diagnostic. Financially, the company continues to report net losses, with a $(9,716) loss for Q1 2025 and $(58,897) for FY 2024, indicating ongoing operational deficits. The substantial number of shares registered for resale suggests a focus on providing liquidity to early investors rather than raising new capital for operations.

Key Financial Figures

• $0.00001 — or “Onconetix”), par value $0.00001 per share (the “Common Stock&rdqu
• $3.6896 — arrant has an initial exercise price of $3.6896 and the Series E Warrant has an initial
• $3 — arrant has an initial exercise price of $3.8576, subject to adjustment, and will e
• $1.84 — Capital Market on December 18, 2025 was $1.84 per share. We recommend that you obtain
• $0.8 m — , the Company had cash of approximately $0.8 million, a working capital deficit of app
• $15.0 million — orking capital deficit of approximately $15.0 million and an accumulated deficit of approxima
• $136.9 million — an accumulated deficit of approximately $136.9 million. During the nine months ended September
• $6.6 million — 0, 2025, the Company used approximately $6.6 million in cash for operating activities. In ad
• $5.5 million — ’s cash balance was approximately $5.5 million. The Company believes that its current
• $17.9 million — ”) and may be able to raise up to $17.9 million in gross proceeds remaining under the E

Filing Documents

• ea0270066-s1a1_onconetix.htm (S-1/A) — 416KB
• ea027006601ex5-1_onconetix.htm (EX-5.1) — 13KB
• ea027006601ex23-1_onconetix.htm (EX-23.1) — 2KB
• ea027006601ex23-2_onconetix.htm (EX-23.2) — 2KB
• ea027006601ex-fee_onconetix.htm (EX-FILING FEES) — 15KB
• image_001.jpg (GRAPHIC) — 4KB
• ex5-1_001.jpg (GRAPHIC) — 10KB
• 0001213900-25-124018.txt ( ) — 592KB
• ea027006601ex-fee_onconetix_htm.xml (XML) — 6KB

RISK FACTORS

RISK FACTORS 6 PIPE FINANCINGS 8

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 17 SELLING STOCKHOLDERS 25 PLAN OF DISTRIBUTION 30 EXPERTS 32 LEGAL MATTERS 32 WHERE YOU CAN FIND MORE INFORMATION 32 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process for the delayed or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix, Inc. and our Common Stock. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of up to 29,778,195 shares of our Common Stock from time to time through any means described in the section entitled “ Plan of Distribution .” We will receive the proceeds from any exercise of the PIPE Warrants for cash, but not from the net exercise of PIPE Warrants on a cashless basis or from the resale of any shares of Common Stock by the Selling Stockholders pursuant to this prospectus or the sale of the shares of Common Stock issuable upon the exercise the PIPE Warrants. However, we will pay the expenses, other than underwriting discounts and commissions, associated with the sale of shares pursuant to this prospectus. We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions “ Where You Can Find More Information ” and “ Incorporation of Certain Information by Reference .” No offer of these securities will be made in any jurisdiction where the offer is not permitted. You should rely only on th